MYC

Across TCGA pan-cancer cohorts, MYC mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated MYC data layer compared with 25 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher MYC mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated MYC expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

HNSC, PDAC, and LSCC are the cancer types where MYC mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	II,III,IV	0.707	0.919	.002	47	view →
PDAC	DFS	Tertile	II,III,IV	0.683	1.000	.010	19	view →
LSCC	DFS	Median	II,III,IV	0.885	0.524	.001	13	view →
LUAD	DFS	Median	III,IV	0.422	0.913	.038	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

MYC–HNSC (OS)

Open the HNSC breakdown →